News and Announcements
Fun Facts about Bitcoin and Crypto
- Published December 18, 2024 4:15AM UTC
- Publisher Wholesale Investor
- Categories Capital Insights, Capital Raising Tips, Landing, Trending
Crypto Investment Trends
At Emergence 2024, I outlined how when it comes to innovation, first, innovators equal the incumbent, then they 10X beyond it.
To celebrate this trend, here are 7 fun facts you may not know about the rise of Bitcoin and how it compares with incumbents, plus a fun fact about Coinbase:
1. Pound for Pound
Bitcoin’s total value has surpassed the monetary base of the British Pound. Who would have thought a digital currency could outweigh the currency of a major global economy?
2. Golden Opportunity
Bitcoin ETFs are catching up to Gold ETFs faster than a sprinter on rocket skates. They’ve achieved in months what took gold ETFs decades. Talk about a digital gold rush!
3. BlackRock’s iShares Bitcoin ETF
IBIT surpassed the AUM of its gold counterpart iShares Gold ETF (IAU) in less than 10 months, a feat that took the gold ETF 20 years to achieve.
4. Two Mining Giants go Head to Head – Bitcoin vs BHP
Bitcoin’s market cap (US1.9T) is now 9.5X bigger than mining giant BHP’s (US$200bn). It’s like David became Goliath but with more zeroes and fewer pickaxes.
5. Index Invasion
Bitcoin’s valuation is approaching that of major stock indices like the FTSE or ASX. It’s as if a digital upstart crashed the party of traditional finance’s most exclusive club.
6. Bitcoin vs Nvidia
In the last week, Bitcoin is trading between $30 to $40 billion dollars worth of volume in every 24-hour period. This is double the amount of trading volume of Nvidia
7. Nasdaq Knockout
Coinbase’s market cap ($73.43B) has now surpassed that of Nasdaq Inc. ($48B). It’s like a student has become a master in the world of financial exchanges!
Trending
Arterial Alchemy: Turning the ‘Ticking Time Bomb’ of Heart Disease into Excretable Waste
Current heart medications thin the “grease” in our blood, but Atherid Therapeutics is building the first biological clearing agent to actually scrub the pipes clean. With human trials slated for 2027, the goal is to make heart attacks a preventable and reversible condition.
Breaking the ‘Bird’s Nest’: How Amplia Therapeutics is Piercing the Shield of Pancreatic Cancer
Led by award-winning drug developer Dr. Chris Burns, Amplia Therapeutics (ASX: ATX) is taking a “one-two punch” approach to one of medicine’s deadliest challenges. By utilizing their lead asset, narmafotinib, to dismantle the protective “bird’s nest” of fibrotic tissue surrounding pancreatic tumors, Amplia has achieved a 35% interim response rate in Phase 2a trials. With FDA Fast Track status and critical survival data expected in 2026, the company is rapidly approaching a major commercial and clinical rerate.
The Australian Life Science Sector: A Structural Convergence of 5 Critical Factors
For a decade, we have watched the foundation being built. Government grants are flowing into research infrastructure. Labs constructed. IP portfolios are growing. Talent returning from global pharma. For most of that decade, the returns were slow, the timelines were long, and the capital was cautious. That era is over. The Australian life science sector […]
Backed By Leading Investment Groups and Family Offices
